The objective of the planned study is to demonstrate if ETVAX®, given with two doses 14 days apart and a booster dose at day 90, is safe and provides protection against moderate-to-severe diarrhoea caused by ETEC. The study is a randomized, placebo-controlled, double-blind, field trial of the vaccine in approximately 5000 children residing in an ETEC-endemic area in The Gambia.

M Jahangir Hossain, Lancet Inf Disease 2026. Efficacy of ETVAX, a vaccine against enterotoxigenic Escherichia coli-positive diarrhoea in Gambian children: a double-blind, randomised, placebo-controlled, phase 2b trial

This study is co funded by  the EU Research and Innovation Framework Program, Horizon 2020 through the European and Developing Countries Clinical Trials Partnership (EDCTP) organization.